EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg ‐Negative Patients With Normal Alanine Aminotransferase: A 48‐Week Randomised Controlled Trial

Qiumin Luo, Wenxiong Xu iD, Yeqiong Zhang, Xiangyong Li, Jing Lai, Jianguo Li, Xingrong Zheng, Hong Deng, Lubiao Chen, Xiang Zhu, Chan Xie iD, Liang Peng iD

Journal of Viral Hepatitis · 2026

DOI: 10.1111/jvh.70141 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Viral Hepatitis, 2026. Verfasst von Qiumin Luo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Alanine Transaminase, Antiviral Agents, Hepatitis B virus. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Program key projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The optimal strategy for chronic hepatitis B virus (HBV) infected patients with negative hepatitis B e‐antigen (HBeAg) and normal alanine aminotransferase (ALT) remains uncertain. This study aimed to evaluate the safety and efficacy of tenofovir alafenamide fumarate (TAF) treatment in this patient population. This prospective, open‐label, randomised controlled trial enrolled HBeAg‐negative patients with normal ALT and randomised them 1:1 to either the treatment group (TAF) or the control group (no treatment). The primary endpoint was the reduction in hepatitis B surface antigen (HBsAg) levels from baseline to week 48. A total of 62 patients were enrolled and followed up by 48 weeks ( n = 31 per group). No serious adverse events were reported. At week 48, there was no significant difference in the change in HBsAg between the treatment and control groups [0.01 (−0.06, 0.05) vs. −0.05 (−0.12, 0.06) log 10 IU/mL, p = 0.354]. However, HBV DNA levels were significantly lower in the treatment group (0 vs. 2.86 log 10 IU/mL, p < 0.001). All patients achieved HBV DNA below 20 IU/mL after treatment. Additionally, chitinase‐3‐like protein 1 level was lower in the treatment group (23.8 vs. 44.8 ng/mL, p = 0.019). TAF was well‐tolerated in HBeAg‐negative patients with normal ALT and low‐level HBV DNA viremia. Treatment for 48 weeks led to a high rate of HBV DNA suppression and may potentially delay liver fibrosis progression. Accordingly, early antiviral treatment may benefit this patient population. Trial Registration: Clinical trial number: NCT 04231565

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicAlanine TransaminaseAntiviral AgentsHepatitis B virusVirus ReplicationTenofovirAdenineHumansMaleFemaleAdultHepatitis B e AntigensMiddle AgedProspective StudiesTreatment OutcomeDNA, ViralAlanineHepatitis B Surface AntigensViral LoadYoung Adult

Stichwörter der Autor:innen

antiviral treatmentchronic HBV infectionefficacyinactivenegative HBeAg

Substanzen

Hepatitis B e AntigensAlanine TransaminaseAntiviral Agentstenofovir alafenamideTenofovirDNA, ViralAlanineAdenineHepatitis B Surface Antigens

Autor:innen und Institutionen

  • Department of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

ORCID-Profile: Wenxiong Xu, Chan Xie, Liang Peng

Förderung

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangzhou Municipal Science and Technology Program key projects
  • Guangzhou Municipal Science and Technology Project
  • Sun Yat-Sen University Clinical Research 5010 Program
  • Five-Year Plan of Third Affiliated Hospital of Sun Yat-sen University

Zitieren

APA

Luo, Q., Xu, W., Zhang, Y., Li, X., Lai, J., Li, J., Zheng, X., Deng, H., Chen, L., Zhu, X., Xie, C., & Peng, L. (2026). Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg ‐Negative Patients With Normal Alanine Aminotransferase: A 48‐Week Randomised Controlled Trial. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70141

Vancouver

Luo Q, Xu W, Zhang Y, Li X, Lai J, Li J, et al. Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg ‐Negative Patients With Normal Alanine Aminotransferase: A 48‐Week Randomised Controlled Trial. Journal of Viral Hepatitis. 2026. doi:10.1111/jvh.70141

BibTeX
@article{Luo2026,
  author = {Luo, Qiumin and Xu, Wenxiong and Zhang, Yeqiong and Li, Xiangyong and Lai, Jing and Li, Jianguo and Zheng, Xingrong and Deng, Hong and Chen, Lubiao and Zhu, Xiang and Xie, Chan and Peng, Liang},
  title = {Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg ‐Negative Patients With Normal Alanine Aminotransferase: A 48‐Week Randomised Controlled Trial},
  journal = {Journal of Viral Hepatitis},
  year = {2026},
  doi = {10.1111/jvh.70141}
}
Kostenlos starten →